Program
Niclosamide
Also written as “Niclosamide Oral Tablet”, “CP-PCA07” and “Niclosamide Inhalation Powder”.
Its studies are mostly in COVID-19 · Prostatic Neoplasms · Colitis, Ulcerative, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Entero Therapeutics | 40 open or running | phase 2since Apr 17, 2018 | Apr 17, 2018 | none ahead |
| NeuroBo Pharmaceuticals | 20 open or running | phase 3since Oct 20, 2020 | Oct 20, 2020 | none ahead |
| Hyundai Bioscience | 11 open or running | phase 1since Jun 23, 2026 | Jun 23, 2026 | Sep 2027phase 1 · NCT07683013 |
| Imuneks Farma ilac San. Tic. A.S. | 10 open or running | phase 3since Sep 18, 2020 | Sep 18, 2020 | none ahead |
| TFF Pharmaceuticals | 10 open or running | phase 1since Dec 20, 2021 | Dec 20, 2021 | none ahead |
| UNION therapeutics | 10 open or running | phase 2since Jun 18, 2021 | Jun 18, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2018First study: phase 2 study in Colitis, UlcerativeNew to Entero TherapeuticsEntero Therapeutics · NCT03521232 · 27 enrolled · Italy
- Jun 16, 2020Phase 2 study in COVIDEntero Therapeutics · NCT04436458
- Sep 4, 2020Phase 2 study in COVID-19Entero Therapeutics · NCT04542434
- Sep 18, 2020Imuneks Farma ilac San. Tic. A.S.'s first study: phase 3 study in COVID-19New to Imuneks Farma ilac San. Tic. A.S.Imuneks Farma ilac San. Tic. A.S. · NCT04558021 · 200 enrolled · Turkey
- Oct 20, 2020NeuroBo Pharmaceuticals's first study: phase 3 study in COVID-19New to NeuroBo PharmaceuticalsNeuroBo Pharmaceuticals · NCT04603924 · 49 enrolled · United States
- Dec 8, 2020Phase 1 study in HealthyNeuroBo Pharmaceuticals · NCT04705415 · 54 enrolled · United States
- Apr 21, 2021Phase 2 study in COVID-19Entero Therapeutics · NCT04858425 · 166 enrolled · United States, India, Ukraine
- Jun 18, 2021UNION therapeutics's first study: phase 2 study in COVID-19New to UNION therapeuticsUNION therapeutics · NCT04932915 · 4 enrolled · Germany
- Dec 20, 2021TFF Pharmaceuticals's first study: phase 1 study in HealthyNew to TFF PharmaceuticalsTFF Pharmaceuticals · NCT05168644 · 40 enrolled · Canada
- Jun 23, 2026Hyundai Bioscience's first study: phase 1 study in Castration-Resistant Prostate Cancer (CRPC)New to Hyundai BioscienceHyundai Bioscience · NCT07683013 · 18 planned · South Korea
Ahead
- Sep 2027Primary completion: phase 1 study in Castration-Resistant Prostate Cancer (CRPC)Hyundai Bioscience · NCT07683013
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07683013Castration-Resistant Prostate Cancer (CRPC) · South Korea | 1 | Not yet recruiting | Hyundai Bioscience | Sep 2027 | 18 |
| NCT05168644Healthy · Canada | 1 | Completed | TFF Pharmaceuticals | Jan 26, 2022 | 40 |
| NCT04932915COVID-19 · Germany | 2 | Terminated | UNION therapeutics | Jan 10, 2022 | 4 |
| NCT04858425COVID-19 · United States, India, Ukraine | 2 | Terminated | Entero Therapeutics | Jun 4, 2022 | 166 |
| NCT04705415Healthy · United States | 1 | Completed | NeuroBo Pharmaceuticals | Oct 13, 2021 | 54 |
| NCT04603924COVID-19 · United States | 3 | Completed | NeuroBo Pharmaceuticals | Feb 16, 2022 | 49 |
| NCT04558021COVID-19 · Turkey | 3 | UNKNOWN | Imuneks Farma ilac San. Tic. A.S. | Jan 30, 2021 | 200 |
| NCT04542434COVID-19 | 2 | Withdrawn | Entero Therapeutics | Jan 20, 2022 | 0 |
| NCT04436458COVID | 2 | Withdrawn | Entero Therapeutics | Jan 20, 2022 | 0 |
| NCT03521232Colitis, Ulcerative · Italy | 2 | Terminated | Entero Therapeutics | Sep 19, 2022 | 27 |
How it is read
Names in the registry
- “Niclosamide”, 5 entries
- “Niclosamide Oral Tablet”, 2 entries
- “CP-PCA07”, 1 entry
- “Niclosamide Inhalation Powder”, 1 entry
- “Niclosamide suspension”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 5 studies
- Prostatic Neoplasms, 1 study
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.